Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Autolus Therapeutics plcNASDAQ: AUTL
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $61.16M rose 8.7% year over year, ahead of the -11.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 14.2% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Operating expenses amounted to 344.6% of revenue in FY2025, down 747.5 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.7% holds above the trailing-twelve-month pace of -11.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 260.41M USD
- Year-over-year change
- +135.6%
- 4-year CAGR
- +16.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 260.41M | +135.6% |
| FY2024 | 2024-12-31 | 110.53M | -39.1% |
| FY2023 | 2023-12-31 | 181.4M | +21.7% |
| FY2022 | 2022-12-31 | 149.09M | +5.1% |
| FY2021 | 2021-12-31 | 141.88M | — |
Operating Expenses vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 operating expenses of $254.35M is the 2nd highest of the 10 companies compared; the peer median is $112.97M.
- Its year-over-year change of -11.1% is the 4th highest of 10, against a peer median of -13.0%.
- Operating expenses amounts to 274.7% of revenue for AUTL, versus a peer median of 183.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $740.02M | -0.1% | +14.3% | 54.5% | |
| LTM Mar 2026 | $254.35M | -11.1% | +20.4% | 274.7% | |
| LTM Mar 2026 | $189.56M | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $140.97M | +26.8% | +7.2% | 1258.3% | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $112.97M | -32.5% | -15.4% | — | |
| LTM Mar 2026 | $101.75M | +11.1% | -1.4% | 149.4% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $82.81M | -13.0% | -1.4% | 183.7% | |
| LTM Mar 2026 | $28.55M | -83.6% | -4.9% | 123.4% | |
| Peer median (excluding AUTL) | $112.97M | -13.0% | -4.9% | 183.7% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.